Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM vs Buccal Midazolam in Pediatric Seizures
NCT02897856Phase 4Completed
- Sponsor
- Hamad Medical Corporation
- Start
- Sep 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of midazolam in epilepsy (2 arms), sponsored by Hamad Medical Corporation. Primary endpoint: Cessation of seizure activity at 5 months. Started Sep 2016; status: completed.
02
Drugs
midazolam
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02897856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02897856.